A number of firms have modified their ratings and price targets on shares of GlaxoSmithKline plc (LON: GSK) recently:

  • 10/23/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 10/23/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Beaufort Securities. They now have a GBX 1,800 ($23.75) price target on the stock.
  • 10/23/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/23/2017 – GlaxoSmithKline plc was given a new GBX 1,600 ($21.11) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 10/18/2017 – GlaxoSmithKline plc was given a new GBX 1,600 ($21.11) price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 10/17/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a GBX 1,900 ($25.07) price target on the stock.
  • 10/16/2017 – GlaxoSmithKline plc had its price target raised by analysts at Jefferies Group LLC from GBX 1,675 ($22.10) to GBX 1,700 ($22.43). They now have a “buy” rating on the stock.
  • 10/12/2017 – GlaxoSmithKline plc was given a new GBX 1,610 ($21.25) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 10/11/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,610 ($21.25) price target on the stock.
  • 10/10/2017 – GlaxoSmithKline plc was given a new GBX 1,550 ($20.45) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 10/4/2017 – GlaxoSmithKline plc had its price target lowered by analysts at Liberum Capital from GBX 1,900 ($25.07) to GBX 1,760 ($23.23). They now have a “buy” rating on the stock.
  • 10/2/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 1,570 ($20.72) price target on the stock.
  • 9/21/2017 – GlaxoSmithKline plc was given a new GBX 1,610 ($21.25) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 9/21/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 9/20/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/20/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,610 ($21.25) price target on the stock.
  • 9/19/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at Bryan, Garnier & Co. They now have a GBX 1,710 ($22.57) price target on the stock.
  • 9/19/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Berenberg Bank. They now have a GBX 1,835 ($24.21) price target on the stock.
  • 9/18/2017 – GlaxoSmithKline plc had its price target lowered by analysts at Jefferies Group LLC from GBX 1,750 ($23.09) to GBX 1,675 ($22.10). They now have a “buy” rating on the stock.
  • 9/14/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/13/2017 – GlaxoSmithKline plc had its price target lowered by analysts at J P Morgan Chase & Co from GBX 1,750 ($23.09) to GBX 1,570 ($20.72). They now have a “neutral” rating on the stock.
  • 9/13/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 1,970 ($26.00) price target on the stock.
  • 9/8/2017 – GlaxoSmithKline plc was given a new GBX 1,600 ($21.11) price target on by analysts at Morgan Stanley. They now have a “sell” rating on the stock.
  • 9/8/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 1,700 ($22.43) price target on the stock.
  • 9/6/2017 – GlaxoSmithKline plc had its price target lowered by analysts at Credit Suisse Group from GBX 1,775 ($23.42) to GBX 1,725 ($22.76). They now have a “neutral” rating on the stock.
  • 9/6/2017 – GlaxoSmithKline plc was given a new GBX 1,620 ($21.38) price target on by analysts at BNP Paribas. They now have a “neutral” rating on the stock.
  • 9/6/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 8/30/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($25.07) price target on the stock.

GlaxoSmithKline plc (LON:GSK) opened at 1519.50 on Tuesday. The stock’s market capitalization is GBX 74.27 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,724.50. The firm’s 50-day moving average is GBX 1,500.92 and its 200 day moving average is GBX 1,578.36.

The firm also recently disclosed a dividend, which was paid on Thursday, October 12th. Investors of record on Thursday, August 10th were given a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend was Thursday, August 10th. This represents a dividend yield of 1.23%.

In other GlaxoSmithKline plc news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The shares were acquired at an average cost of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Also, insider Manvinder Singh Banga acquired 2,267 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was acquired at an average price of GBX 1,599 ($21.10) per share, for a total transaction of £36,249.33 ($47,834.96). Insiders purchased a total of 3,368 shares of company stock worth $5,305,807 over the last quarter.

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.